Identification and characterization of a novel botulinum neurotoxin

Botulinum neurotoxins are known to have seven serotypes (BoNT/A–G). Here we report a new BoNT serotype, tentatively named BoNT/X, which has the lowest sequence identity with other BoNTs and is not recognized by antisera against known BoNTs. Similar to BoNT/B/D/F/G, BoNT/X cleaves vesicle-associated membrane proteins (VAMP) 1, 2 and 3, but at a novel site (Arg66-Ala67 in VAMP2). Remarkably, BoNT/X is the only toxin that also cleaves non-canonical substrates VAMP4, VAMP5 and Ykt6. To validate its activity, a small amount of full-length BoNT/X was assembled by linking two non-toxic fragments using a transpeptidase (sortase). Assembled BoNT/X cleaves VAMP2 and VAMP4 in cultured neurons and causes flaccid paralysis in mice. Thus, BoNT/X is a novel BoNT with a unique substrate profile. Its discovery posts a challenge to develop effective countermeasures, provides a novel tool for studying intracellular membrane trafficking, and presents a new potential therapeutic toxin for modulating secretions in cells.

[1]  C. Montecucco,et al.  Botulinum neurotoxins: genetic, structural and mechanistic insights , 2014, Nature Reviews Microbiology.

[2]  T. Karasawa,et al.  Characterization of Clostridium botulinum Type B Neurotoxin Associated with Infant Botulism in Japan , 1998, Infection and Immunity.

[3]  T. Südhof,et al.  Membrane Fusion: Grappling with SNARE and SM Proteins , 2009, Science.

[4]  R. Collier,et al.  Receptor-Directed Chimeric Toxins Created by Sortase-Mediated Protein Fusion , 2013, Molecular Cancer Therapeutics.

[5]  Leonard A. Smith,et al.  Analysis of the Neurotoxin Complex Genes in Clostridium botulinum A1-A4 and B1 Strains: BoNT/A3, /Ba4 and /B1 Clusters Are Located within Plasmids , 2007, PloS one.

[6]  M. Dorner,et al.  Molecular basis for disruption of E-cadherin adhesion by botulinum neurotoxin A complex , 2014, Science.

[7]  Brian H. Raphael,et al.  Neurotoxin Gene Clusters in Clostridium botulinum Type Ab Strains , 2009, Applied and Environmental Microbiology.

[8]  Reinhard Jahn,et al.  SNAREs — engines for membrane fusion , 2006, Nature Reviews Molecular Cell Biology.

[9]  Eric A. Johnson,et al.  Recombinant Holotoxoid Vaccine against Botulism , 2007, Infection and Immunity.

[10]  T. Gillingwater,et al.  VAMP4 Is an Essential Cargo Molecule for Activity-Dependent Bulk Endocytosis , 2015, Neuron.

[11]  Hidde L Ploegh,et al.  Sortagging: a versatile method for protein labeling. , 2007, Nature chemical biology.

[12]  K. Yamakawa,et al.  The first case of type B infant botulism in Japan , 1996, Acta paediatrica Japonica : Overseas edition.

[13]  G. Schiavo,et al.  Neurotoxins affecting neuroexocytosis. , 2000, Physiological reviews.

[14]  B. Foley,et al.  Genetic diversity within the botulinum neurotoxin-producing bacteria and their neurotoxins. , 2015, Toxicon : official journal of the International Society on Toxinology.

[15]  R. Scheller,et al.  Vesicle-associated membrane protein 4 is implicated in trans-Golgi network vesicle trafficking. , 1999, Molecular biology of the cell.

[16]  Eric A. Johnson,et al.  Plasmid encoded neurotoxin genes in Clostridium botulinum serotype A subtypes. , 2007, Biochemical and biophysical research communications.

[17]  F. Benfenati,et al.  Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin , 1992, Nature.

[18]  C. A. Smith,et al.  Bacteriophage and the Toxigenicity of Clostridium botulinum Type C , 1971, Science.

[19]  N. Dover,et al.  Clostridium botulinum Strain Af84 Contains Three Neurotoxin Gene Clusters: Bont/A2, bont/F4 and bont/F5 , 2013, PloS one.

[20]  S. Lindquist,et al.  α-Synuclein Blocks ER-Golgi Traffic and Rab1 Rescues Neuron Loss in Parkinson's Models , 2006, Science.

[21]  Giampietro Schiavo,et al.  SNARE motif and neurotoxins , 1994, Nature.

[22]  G. S. Burke.  NOTES ON BACILLUS BOTULINUS , 1919, Journal of bacteriology.

[23]  D. James,et al.  A novel synaptobrevin/VAMP homologous protein (VAMP5) is increased during in vitro myogenesis and present in the plasma membrane. , 1998, Molecular biology of the cell.

[24]  D. F. Giménez,et al.  Another type of Clostridium botulinum. , 1970, Zentralblatt fur Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene. 1. Abt. Medizinisch-hygienische Bakteriologie, Virusforschung und Parasitologie. Originale.

[25]  Hideyuki Yamamoto,et al.  Specificity of botulinum protease for human VAMP family proteins , 2012, Microbiology and immunology.

[26]  S. Arnon,et al.  A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins. , 2014, The Journal of infectious diseases.

[27]  S. Rizzoli,et al.  Homotypic fusion of early endosomes: SNAREs do not determine fusion specificity. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Leonard A. Smith,et al.  Sequence Variation within Botulinum Neurotoxin Serotypes Impacts Antibody Binding and Neutralization , 2005, Infection and Immunity.

[29]  E. Johnson,et al.  Clostridial toxins as therapeutic agents: benefits of nature's most toxic proteins. , 1999, Annual review of microbiology.

[30]  K. Tóth,et al.  VAMP4 directs synaptic vesicles to a pool that selectively maintains asynchronous neurotransmission , 2012, Nature Neuroscience.

[31]  M. Collins,et al.  Genetic Characterization of Clostridium botulinum Type A Containing Silent Type B Neurotoxin Gene Sequences (*) , 1996, The Journal of Biological Chemistry.

[32]  L. O. Ticknor,et al.  Genetic Diversity among Botulinum Neurotoxin-Producing Clostridial Strains , 2006, Journal of bacteriology.

[33]  A. Linstedt.  Faculty Opinions recommendation of Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. , 2006 .

[34]  J. Strominger,et al.  VAMP4‐ and VAMP7‐expressing vesicles are both required for cytotoxic granule exocytosis in NK cells , 2011, European journal of immunology.

[35]  Mauricio Montal,et al.  Botulinum neurotoxin: a marvel of protein design. , 2010, Annual review of biochemistry.

[36]  C. Montecucco,et al.  On Botulinum Neurotoxin Variability , 2015, mBio.

[37]  C. Montecucco,et al.  Botulinal neurotoxins: revival of an old killer. , 2005, Current opinion in pharmacology.

[38]  K. Aoki,et al.  A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice. , 2001, Toxicon : official journal of the International Society on Toxinology.

[39]  Philip K. Russell,et al.  Botulinum toxin as a biological weapon: medical and public health management. , 2001, JAMA.

[40]  J. Alves,et al.  Arg(362) and Tyr(365) of the botulinum neurotoxin type a light chain are involved in transition state stabilization. , 2002, Biochemistry.

[41]  C. Shoemaker,et al.  Botulinum Neurotoxin Is Shielded by NTNHA in an Interlocked Complex , 2012, Science.

[42]  J. Hay,et al.  α-Synuclein Delays Endoplasmic Reticulum (ER)-to-Golgi Transport in Mammalian Cells by Antagonizing ER/Golgi SNAREs , 2010, Molecular biology of the cell.

[43]  Brian H. Raphael,et al.  A Novel Botulinum Neurotoxin, Previously Reported as Serotype H, Has a Hybrid-Like Structure With Regions of Similarity to the Structures of Serotypes A and F and Is Neutralized With Serotype A Antitoxin. , 2016, The Journal of infectious diseases.

[44]  Gary Xie,et al.  Molecular characterization of a novel botulinum neurotoxin type H gene. , 2014, The Journal of infectious diseases.

[45]  Brian H. Raphael,et al.  Analysis of Neurotoxin Cluster Genes in Clostridium botulinum Strains Producing Botulinum Neurotoxin Serotype A Subtypes , 2008, Applied and Environmental Microbiology.

[46]  Brian H. Raphael,et al.  Functional characterization of botulinum neurotoxin serotype H as a hybrid of known serotypes F and A (BoNT F/A). , 2015, Analytical chemistry.

[47]  H. Sugiyama,et al.  The genes for the Clostridium botulinum type G toxin complex are on a plasmid , 1995, Infection and immunity.

[48]  H. Bigalke,et al.  The HCC‐domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction , 2003, Molecular microbiology.

[49]  Eric A. Johnson.  Benefits of Nature's Most Toxic Proteins , 1999 .

[50]  J. Meldolesi,et al.  The regulated exocytosis of enlargeosomes is mediated by a SNARE machinery that includes VAMP4 , 2008, Journal of Cell Science.

[51]  C. Hatheway,et al.  Detection of type A, B, and E botulism neurotoxin genes in Clostridium botulinum and other Clostridium species by PCR: evidence of unexpressed type B toxin genes in type A toxigenic organisms , 1994, Journal of clinical microbiology.

[52]  M. Takeichi,et al.  Botulinum hemagglutinin disrupts the intercellular epithelial barrier by directly binding E-cadherin , 2010, The Journal of cell biology.

[53]  T. Karasawa,et al.  Sequence of the gene for Clostridium botulinum type B neurotoxin associated with infant botulism, expression of the C-terminal half of heavy chain and its binding activity. , 2003, Biochimica et biophysica acta.

[54]  T. Galli,et al.  Structure and function of longin SNAREs , 2015, Journal of Cell Science.

[55]  Giménez Df,et al.  Another type of Clostridium botulinum. , 1970 .

[56]  Lei Jin,et al.  Structure of a Bimodular Botulinum Neurotoxin Complex Provides Insights into Its Oral Toxicity , 2013, PLoS pathogens.

[57]  Eric A. Johnson,et al.  Botulinum Neurotoxin D Uses Synaptic Vesicle Protein SV2 and Gangliosides as Receptors , 2011, PLoS pathogens.

[58]  N. Dover,et al.  Molecular epidemiology of infant botulism in California and elsewhere, 1976-2010. , 2014, The Journal of infectious diseases.

[59]  C. Quinn,et al.  Expression and purification of catalytically active, non-toxic endopeptidase derivatives of Clostridium botulinum toxin type A. , 2002, Protein expression and purification.

[60]  N. Dover,et al.  Identical Novel A5(B3′) Botulinum Neurotoxin Gene Arrangements Isolated from Widely Disparate Geographical and Patient Sources Suggest Their Independent Origins , 2010, Journal of Clinical Microbiology.